Tags

Type your tag names separated by a space and hit enter

Blood and marrow transplantation activity in Europe 1997. European Group for Blood and Marrow Transplantation (EBMT).
Bone Marrow Transplant. 1999 Aug; 24(3):231-45.BM

Abstract

Data from the annual survey on transplant activity 1997, collected from 457 transplant teams in 31 European countries by the European Group for Blood and Marrow Transplantation (EBMT) were used to describe current status and to assess relative and absolute changes in indication, donor type and stem cell source compared to 1991. A total of 16950 patients were reported to have a first blood or marrow transplant in 1997, a total of 18 923 procedures, including re- and double transplants were performed. Of the 16950 first transplants, 4751 (28%) were allogeneic, 12199 (72%) autologous transplants. Of the autologous transplants, 829 (7%) were bone marrow derived, 11370 (93%) from peripheral blood stem cells or combined bone marrow and peripheral blood stem cell transplants. Of the allogeneic transplants, 3311 (70%) were bone marrow, 1440 (30%) were peripheral blood stem cell transplants. In 1991, the respective figures were 2175 allogeneic (44%) and 2786 (56%) autologous transplants, more than 90% of the autologous, all allogeneic transplants bone marrow derived. Main indications in 1997 were leukemias with 5253 transplants (31%), 70% allogeneic; lymphomas with 6773 transplants (40%), 94% autologous; solid tumors with 4154 transplants (24%), 99% autologous; non-malignant disorders with 770 transplants (5 %), 85 % allogeneic. There was an absolute increase of 11971 transplants since 1991. An increase was observed in all disease categories. Marked differences were found, when the relative increase index (RII) for specific disease categories over time was analyzed. In allogeneic transplants, relatively more transplants were performed in 1997 for acute myeloid leukemia beyond 1st complete remission (RII 1.28), myelodysplastic syndromes (RII 1.58), chronic lymphocytic leukemia (RII 1.33) and non-Hodgkin's lymphoma (RII 1.58). For autologous transplant indications, a high relative increase index was observed in myelodysplastic syndromes (RII 3.77), in multiple myeloma (RII 2.12) and carcinoma of the breast (RII 6.37) with a relative decrease in leukemias (RII 0.39) and certain solid tumors such as glioma (RII 0.27) and neuroblastoma (RII 0.46). These data present the current status of blood and marrow transplantation in Europe. They show the change from bone marrow to blood as stem cell source and highlight shifts in indication. They provide a basis for patient counselling and health care planning.

Authors+Show Affiliations

Department of Internal Medicine, Kantonsspital Basel, Switzerland.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10456992

Citation

Gratwohl, A, et al. "Blood and Marrow Transplantation Activity in Europe 1997. European Group for Blood and Marrow Transplantation (EBMT)." Bone Marrow Transplantation, vol. 24, no. 3, 1999, pp. 231-45.
Gratwohl A, Passweg J, Baldomero H, et al. Blood and marrow transplantation activity in Europe 1997. European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1999;24(3):231-45.
Gratwohl, A., Passweg, J., Baldomero, H., & Hermans, J. (1999). Blood and marrow transplantation activity in Europe 1997. European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 24(3), 231-45.
Gratwohl A, et al. Blood and Marrow Transplantation Activity in Europe 1997. European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1999;24(3):231-45. PubMed PMID: 10456992.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Blood and marrow transplantation activity in Europe 1997. European Group for Blood and Marrow Transplantation (EBMT). AU - Gratwohl,A, AU - Passweg,J, AU - Baldomero,H, AU - Hermans,J, PY - 1999/8/24/pubmed PY - 1999/8/24/medline PY - 1999/8/24/entrez SP - 231 EP - 45 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 24 IS - 3 N2 - Data from the annual survey on transplant activity 1997, collected from 457 transplant teams in 31 European countries by the European Group for Blood and Marrow Transplantation (EBMT) were used to describe current status and to assess relative and absolute changes in indication, donor type and stem cell source compared to 1991. A total of 16950 patients were reported to have a first blood or marrow transplant in 1997, a total of 18 923 procedures, including re- and double transplants were performed. Of the 16950 first transplants, 4751 (28%) were allogeneic, 12199 (72%) autologous transplants. Of the autologous transplants, 829 (7%) were bone marrow derived, 11370 (93%) from peripheral blood stem cells or combined bone marrow and peripheral blood stem cell transplants. Of the allogeneic transplants, 3311 (70%) were bone marrow, 1440 (30%) were peripheral blood stem cell transplants. In 1991, the respective figures were 2175 allogeneic (44%) and 2786 (56%) autologous transplants, more than 90% of the autologous, all allogeneic transplants bone marrow derived. Main indications in 1997 were leukemias with 5253 transplants (31%), 70% allogeneic; lymphomas with 6773 transplants (40%), 94% autologous; solid tumors with 4154 transplants (24%), 99% autologous; non-malignant disorders with 770 transplants (5 %), 85 % allogeneic. There was an absolute increase of 11971 transplants since 1991. An increase was observed in all disease categories. Marked differences were found, when the relative increase index (RII) for specific disease categories over time was analyzed. In allogeneic transplants, relatively more transplants were performed in 1997 for acute myeloid leukemia beyond 1st complete remission (RII 1.28), myelodysplastic syndromes (RII 1.58), chronic lymphocytic leukemia (RII 1.33) and non-Hodgkin's lymphoma (RII 1.58). For autologous transplant indications, a high relative increase index was observed in myelodysplastic syndromes (RII 3.77), in multiple myeloma (RII 2.12) and carcinoma of the breast (RII 6.37) with a relative decrease in leukemias (RII 0.39) and certain solid tumors such as glioma (RII 0.27) and neuroblastoma (RII 0.46). These data present the current status of blood and marrow transplantation in Europe. They show the change from bone marrow to blood as stem cell source and highlight shifts in indication. They provide a basis for patient counselling and health care planning. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/10456992/Blood_and_marrow_transplantation_activity_in_Europe_1997__European_Group_for_Blood_and_Marrow_Transplantation__EBMT__ L2 - https://doi.org/10.1038/sj.bmt.1701866 DB - PRIME DP - Unbound Medicine ER -